GoalVest Advisory LLC Has $1.66 Million Position in AbbVie Inc. $ABBV

GoalVest Advisory LLC lessened its stake in AbbVie Inc. (NYSE:ABBV) by 48.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 6,577 shares of the company’s stock after selling 6,171 shares during the period. GoalVest Advisory LLC’s holdings in AbbVie were worth $1,655,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Ranch Capital Advisors Inc. lifted its position in AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after purchasing an additional 4,017 shares during the period. Calamos Advisors LLC boosted its stake in shares of AbbVie by 3.4% in the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock valued at $106,543,000 after purchasing an additional 15,458 shares during the last quarter. Bingham Private Wealth LLC acquired a new stake in shares of AbbVie during the 4th quarter worth approximately $1,147,000. Axecap Investments LLC grew its position in shares of AbbVie by 713.2% during the 4th quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock worth $3,729,000 after buying an additional 14,313 shares during the period. Finally, Legacy Edge Advisors LLC bought a new stake in shares of AbbVie during the fourth quarter worth approximately $1,265,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $245.82 on Friday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The stock has a market cap of $434.31 billion, a P/E ratio of 69.44, a P/E/G ratio of 0.82 and a beta of 0.30. The firm has a 50 day moving average price of $241.96 and a 200 day moving average price of $224.96.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Analysts Set New Price Targets

ABBV has been the topic of several analyst reports. Barclays increased their price objective on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday. HSBC reiterated a “buy” rating and set a $300.00 target price on shares of AbbVie in a research report on Monday, July 6th. Bank of America raised their price target on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Royal Bank Of Canada lifted their price objective on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $275.70.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.